Skip to main content
SpringerLink
Log in

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

  • Special Articles
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1). The oxidation of more than 20 clinically useful drugs has now been shown to be under similar genetic control to that of sparteine/debrisoquine. The clinical significance of this polymorphism may be defined by the value of phenotyping patients before treatment. The clinical significance of such polymorphic elimination of a particular drug can be analyzed in three steps: first, does the kinetics of active principle of a drug depend significantly on P450db1?; second, is the resulting pharmacokinetic variability of any clinical importance?; and third, can the variation in response be assessed by direct clinical or paraclinical measurements? It is concluded from such an analysis that, in general, the sparteine/debrisoquine oxidation polymorphism is of significance in patient management only for those drugs for which plasma concentration measurements are considered useful and for which the elimination of the drug and/or its active metabolite is mainly determined by P450db1. At present, this applies to tricyclic antidepressants and to certain neuroleptics (e.g. perphenazine and thioridazine) and antiarrhythmics (e.g. propafenone and flecainide). Phenotyping should be introduced in to clinical routine under strictly controlled conditions to afford a better understanding of its potentials and limitations. The increasing knowledge of specific substrates and inhibitors of P450db1 allows precise predictions of drug-drug interactions. At present, the strong inhibitory effect of neuroleptics on the metabolism of tricyclic antidepressants represents the best clinically documented and most relevant example of such an interaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alván G, Grind M, Graffner C, Sjöqvist F (1984) Relationship ofN-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 36: 515–519

    Google Scholar 

  • Back DJ, Maggs JL, Purba HS, Newby S, Park BK (1984) 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine. Br J Clin Pharmacol 18: 603–607

    Google Scholar 

  • von Bahr C, Spina E, Birgersson C (1985) Inhibition of desmethylimipramine 2-hydroxolation by drugs in human liver microsomes. Biochem Pharmacol 14: 2501–2505

    Google Scholar 

  • von Bahr C, Guengerich FP, Morin G, Nordin C (1989) The use of human liver banks in pharmacogenetic research. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo (in press)

    Google Scholar 

  • Balant LP, Gundert-Remy U, Boobis AR, von Bahr C (1989) Genetic polymorphism in drug metabolism: Relevance for the development of new drugs. Eur J Clin Pharmacol (in press)

  • Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G (1986) Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31: 449–455

    Google Scholar 

  • Baumann P, Jonzier-Perey M, Koeb L, Küpfer A, Tinguely D, Schöpf J (1986) Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1: 102–112

    Google Scholar 

  • Beckmann J, Hertrampf R, Gundert-Remy U, Mikus G, Gross AS, Eichelbaum M (1988) Is there a genetic factor in flecainide toxicity? Br Med J 297: 1316

    Google Scholar 

  • Beerahee M, Wilkins MR, Jack DB, Beevers DG, Kendall MJ (1987) Twelve hour (through) plasma nifedipine concentrations during chronic treatment with nifedipine retard. Eur J Clin Pharmacol 32: 347–349

    Google Scholar 

  • Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27: 1673–1677

    Google Scholar 

  • Bertilsson L, Åberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 15: 388–390

    Google Scholar 

  • Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 478–480

    Google Scholar 

  • Bertilsson L, Henthorn TK, Sanch E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther (in press)

  • Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 23: 474–481

    Google Scholar 

  • Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22: 194–197

    Google Scholar 

  • Brøsen K, Otton SV, Gram LF (1986a) Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40: 543–549

    Google Scholar 

  • Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L (1986b) Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30: 679–684

    Google Scholar 

  • Brøsen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizer during quinidine treatment. Pharmacol Toxicol 60: 312–314

    Google Scholar 

  • Brøsen K, Gram LF (1988) First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43: 400–406

    Google Scholar 

  • Clark DWJ, Morgan AKW, Waal-Manning H (1984) Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 18: 965–967

    Google Scholar 

  • Cooper RG, Evans DAP, Price AH (1987) Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32: 569–576

    Google Scholar 

  • Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11: 36–61

    Google Scholar 

  • Dahl-Puustinen ML, Lidén A, Alm C, Bertilsson L (1989) Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in man. Clin Pharmacol Ther (in press)

  • Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F (1984) Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther 35: 815–821

    Google Scholar 

  • Danhof M, Idle JR, Teunissen MWE, Sloan TP, Breimer DD, Smith RL (1981) Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology 22: 349–358

    Google Scholar 

  • Dayer P, Balant L, Kupfer A, Striberni R, Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin PHarmacol 28: 317–320

    Google Scholar 

  • Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 152: 411–416

    Google Scholar 

  • Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P450 function (debrisoquine-sparteine type of polymorphism). Biochem Biophys Res Commun 125: 374–380

    Google Scholar 

  • Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979a) DefectiveN-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Google Scholar 

  • Eichelbaum M, Spannbrucker N, Dengler HJ (1979b) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16: 189–194

    Google Scholar 

  • Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186

    Google Scholar 

  • Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10: 80–90

    Google Scholar 

  • Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 49–53

    Google Scholar 

  • Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  • Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3855

    Google Scholar 

  • Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ (1987) Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci USA 84: 7920–7924

    Google Scholar 

  • Gabris G, Baumann P, Jonzier-Perey M, Bosshart P, Woggon B, Küpfer A (1985) N-Methylation of maprotiline in debrisoquine/mephenytoin-phenotyped depressive patients. Biochem Pharmacol 34: 409–410

    Google Scholar 

  • Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR (1985) Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development. Br J Clin Pharmacol 20: 81–84

    Google Scholar 

  • Gonzalez FJ, Skoda R, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446

    Google Scholar 

  • Gram LF (1975) Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175

    Google Scholar 

  • Gram LF, Brøsen K (1989) Inhibitors of the microsomal oxidation of psychotropic drugs: Selectivity and clinical significance. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo (in press)

    Google Scholar 

  • Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27: 272–275

    Google Scholar 

  • Gram LF, Kragh-Sørensen P, Kristensen CB, Møller M, Pedersen OL, Thayssen P (1984) Plasma level monitoring of antidepressants: Theoretical basis and clinical application. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 399–411

    Google Scholar 

  • Gram LF, Overø KF (1972) Drug interaction: Inhibitory of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 163: 463–465

    Google Scholar 

  • Hirschowitz J, Bennet JA, Semian FP, Garber D (1983) Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol 3: 376–379

    Google Scholar 

  • Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro studies of two isozymes of human liver cytochrome P-450-mephenytoin hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443–448

    Google Scholar 

  • Inaba T, Otton SV, Kalow W (1980) Deficient metabolism of sparteine and debrisoquine. Clin Pharmacol Ther 27: 547–549

    Google Scholar 

  • Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387–394

    Google Scholar 

  • Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Pharmacol 22: 541–550

    Google Scholar 

  • Kitchen I, Tremblay J, André, Dring LG, Idle JR, Smith RL, Williams RT (1979) Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 7: 397–404

    Google Scholar 

  • Knodell RG, Raghvendra KD, Wilkinson GR, Guengerich FP (1988) Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 245: 845–849

    Google Scholar 

  • Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45: 28–33

    Google Scholar 

  • Kronbach T, Fisher V, Meyer UA (1988) Cyclosporine metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine metabolizing enzyme explaining interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635

    Google Scholar 

  • Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759

    Google Scholar 

  • Küpfer A, Branch RA (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38: 414–418

    Google Scholar 

  • Leemann TP, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739–741

    Google Scholar 

  • Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 34: 732–737

    Google Scholar 

  • Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF (1984) The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 17: 679–685

    Google Scholar 

  • Lennard MS, McGourty JC, Silas JH (1988) Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin. Br J Clin Pharmacol 25: 276–278

    Google Scholar 

  • Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1985) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 19: 329–333

    Google Scholar 

  • Lou YC, Ying L, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852–853

    Google Scholar 

  • Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    Google Scholar 

  • Mellström B, Bertilsson L, Lou Y-C, Säwe J, Sjöqvist F (1983) Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 34: 516–520

    Google Scholar 

  • Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T (1986) The molecular mechanisms of two common polymorphisms of drug oxidation — evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464

    Google Scholar 

  • Mikus G, Ha HR, Vozeh S, Zekorn F, Follath F, Eichelbaum M (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 31: 69–72

    Google Scholar 

  • Miners JO, Wing LMH, Birkett DJ (1985) Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Austr NZ J Med 15: 348–349

    Google Scholar 

  • Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    Google Scholar 

  • Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gonsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR (1987) The P450 gene super family: Recommended nomenclature. DNA 6: 1–11

    Google Scholar 

  • Nordin C, Siwers B, Benitz J, Bertilsson L (1985) Plasma concentrations of nortriptyline and its 10-hydroxymetabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 19: 832–835

    Google Scholar 

  • Oates NS, Shah RR, Idle JR, Smith RL (1983) Influence of oxidation polymophism on phenformin kinetics and dynamics. Clin Pharmacol Ther 34: 827–834

    Google Scholar 

  • Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL (1982) Metabolic oxidation of methaqualone in extensive and poor metabolizers of debrisoquine. Eur J Clin Pharmacol 23: 147–150

    Google Scholar 

  • Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80

    Google Scholar 

  • Pierce DM, Smith SE, Franklin RA (1987) The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 33: 59–65

    Google Scholar 

  • Preskorn S (1989) Therapeutic drug monitoring of tricyclic antidepressants: A means of avoiding toxicity. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo, in press

    Google Scholar 

  • Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK (1985) Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Clin Pharmacol Ther 38: 128–133

    Google Scholar 

  • Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segretation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618–624

    Google Scholar 

  • Shaheen O, Patel J, Avant GR, Hamilton M, Wood AJJ (1986) Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. Clin Pharmacol Ther 40: 650–655

    Google Scholar 

  • Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791

    Google Scholar 

  • Siris SG, Cooper TB, Rifbein AE, Brenner R, Liebermann JA (1982) Plasma imipramine concentration in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry 139: 104–106

    Google Scholar 

  • Sjöqvist F, Bertilsson L (1986) Slow hydroxylation of tricylic anti-depressants — Relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP (eds) Ethnic differences in reactions to drugs and xenobiotics. Alan R. Liss, New York, pp 169–188

    Google Scholar 

  • Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2: 655–657

    Google Scholar 

  • Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15: 443–450

    Google Scholar 

  • Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 22: 739–743

    Google Scholar 

  • Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38: 394–401

    Google Scholar 

  • Steiner E, Alván G, Garle M, Maguire JH, Lind M, Nilson S-O, Tomson T, McClanahan JS, Sjöqvist F (1987) The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther 42: 326–333

    Google Scholar 

  • Steiner E, Dumont E, Spina E, Dahlqvist R (1988a) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43: 577–581

    Google Scholar 

  • Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988b) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435

    Google Scholar 

  • Syvählahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22: 89–92

    Google Scholar 

  • Wagner F, Kalusche D, Trenk D, Jänchen E, Roskamm H (1987a) Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24: 213–220

    Google Scholar 

  • Wagner F, Jänchen E, Trenk D (1987b) Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem and sparteine. Klin Wochenschr 65: 1164–1168

    Google Scholar 

  • Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR (1984) Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 228: 605–611

    Google Scholar 

  • Webb NR, Rose TM, Malik N, Marquardt H, Shoyab M, Todaro GJ, Lee DC (1987) Bovine and human cDNA sequences encoding a putative benzodiazepine receptor ligand. DNA 6: 71–79

    Google Scholar 

  • Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450buf I causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454

    Google Scholar 

  • Zekorn C, Achtert G, Hausleiter HJ, Moon CH, Eichelbaum M (1985) Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr 63: 1180–1186

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Odense University, Odense, Denmark

    K. Brøsen & L. F. Gram

Authors
  1. K. Brøsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. F. Gram
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brøsen, K., Gram, L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36, 537–547 (1989). https://doi.org/10.1007/BF00637732

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00637732

Key words

Search

Navigation